What Is a Prostate Biopsy Tool & How Does It Work?

A prostate biopsy tool is a spring-loaded device that fires a hollow needle into the prostate gland, captures a thin cylinder of tissue, and retracts in a fraction of a second. The modern version traces back to the late 1980s, when the “Biopty gun” paired with transrectal ultrasound dramatically improved cancer detection compared to older aspiration methods. Since then, the core concept has stayed the same while the guidance systems, access routes, and needle engineering around it have evolved considerably.

How the Spring-Loaded Needle Actually Works

The biopsy device you are most likely to encounter uses an 18-gauge needle, which is roughly the diameter of a standard sewing pin. Inside the device, a coiled spring is cocked and locked. When the urologist or radiologist presses the trigger, the spring releases in two rapid stages. First, an inner stylet (a solid rod with a small notch near its tip) shoots forward into the prostate tissue. Tissue bulges into the notch. A split second later, an outer cutting cannula slides over the stylet, slicing the tissue cleanly and trapping it inside the notch. The entire firing sequence is nearly instantaneous, which is part of the point: speed reduces the tissue deformation that happens when a needle pushes slowly into soft material.

The speed of needle insertion matters for sample quality. Research into the biomechanics of biopsy needles has shown that insertion velocity affects how much the surrounding tissue shifts and deforms as the needle moves through it, and the beveled geometry of the needle tip influences how far the needle drifts from its intended straight-line target. Friction between the needle and tissue also plays a role in how cleanly the core is captured.¹ The result, when everything works well, is a tissue cylinder roughly 1 to 2 centimeters long and just over a millimeter wide.

One persistent concern among urologists was whether the first half-centimeter of the core might be a “skip area” with no usable tissue, since the stylet notch does not begin right at the needle tip. A study testing this directly on biopsy specimens found confirmed tissue present through the entire length of the core, including that first half-centimeter, effectively debunking the skip-area myth.²

The Biopty Gun and Why It Changed Everything

Before spring-loaded biopsy devices existed, prostate sampling relied on fine-needle aspiration, which draws out loose cells rather than intact tissue cores. The shift came in the late 1980s when researchers paired the Biopty device, which used an 18-gauge Tru-Cut-style needle with an automatic spring mechanism, with high-resolution transrectal ultrasound. In a head-to-head comparison, the spring-loaded core biopsy detected 89 percent of cancers, while the aspiration method caught only 51 percent. That gap was enormous, and it effectively ended the aspiration era for prostate sampling.³ Core biopsies give pathologists intact tissue architecture, letting them assess not just whether cancer cells are present but how they are organized, which is critical for grading aggressiveness.

Imaging Guidance and Targeting

The biopsy needle itself is only half the equation. You also need a way to see where the needle is going. The most common approach for decades has been transrectal ultrasound, where a probe inserted into the rectum generates real-time images of the prostate. Ultrasound probes come in two main designs. Side-fire probes limit the needle to a single plane along the length of the probe, while end-fire probes allow the needle to pivot and take cores in additional orientations, giving the operator more flexibility in reaching different zones of the gland.⁴

Standard ultrasound, however, cannot reliably distinguish cancerous tissue from normal tissue. That limitation drove the development of MRI-ultrasound fusion, where a pre-biopsy MRI scan (which is much better at identifying suspicious lesions) is digitally overlaid onto the live ultrasound image. A registration system tracks the three-dimensional position of each biopsy core within the prostate volume, allowing the urologist to steer the needle toward specific MRI-identified targets rather than sampling blindly.⁵

Software Fusion Versus Cognitive Fusion

Fusion targeting can be done in two ways. Software-based fusion uses a computer platform to physically overlay the MRI onto the ultrasound in real time. Cognitive fusion relies on the operator mentally correlating MRI findings with the live ultrasound image, essentially eyeballing the target location based on experience. A large multicenter randomized trial found that cognitive fusion was statistically noninferior to software-based fusion for detecting clinically significant prostate cancer, with detection rates of about 32 percent and 34 percent respectively.⁶ However, the picture is not completely settled. A separate randomized trial in patients who had never been biopsied before found that software-based fusion detected significantly more cancers than cognitive fusion, with overall detection rates of about 44 percent versus 31 percent.⁷ The difference may come down to operator skill and experience; in expert hands, the cognitive approach can match the software, but less experienced practitioners likely benefit from the computer assist.

Micro-Ultrasound

A newer imaging approach skips MRI entirely and instead upgrades the ultrasound itself. Devices like the ExactVu system operate at 29 MHz, roughly three times the frequency of conventional transrectal ultrasound at 8 to 12 MHz. The higher frequency produces about three times the spatial resolution, enough to reveal subtle changes in the prostate’s ductal anatomy that can signal cancer, while still maintaining enough imaging depth to visualize the entire gland. This allows the operator to target suspicious areas in real time without needing a separate MRI scan beforehand.⁸

Access Routes and How They Affect the Procedure

There are two main paths for the biopsy needle to reach the prostate. In the transrectal approach, the needle passes through the rectal wall. In the transperineal approach, the needle enters through the perineum, the patch of skin between the scrotum and the anus. Both reach the same gland, but the route matters for infection risk, pain management, and which parts of the prostate are easiest to sample.

The transrectal approach has been the standard for decades because it requires less equipment and can often be done in an office setting. The transperineal approach has gained ground because it avoids passing through the bacteria-rich rectal wall, which reduces the risk of post-biopsy infection. Transperineal access systems come in two flavors: grid-template devices, which use a fixed grid pressed against the perineum to guide needle placement at specific coordinates, and freehand systems like the PrecisionPoint, which let the operator angle the needle manually through a stabilizing access point. A study comparing the two found no overall difference in cancer detection, though the grid-based approach detected more clinically significant cancers in patients who had previously had a negative biopsy.⁹

Does Needle Size Matter?

Most prostate biopsies use an 18-gauge needle, but 16-gauge needles (slightly thicker) are also available. You might assume a thicker needle would capture more tissue and detect more cancers, and indeed 16-gauge needles do yield tissue specimens with a larger cross-sectional area. One MRI-guided biopsy study found that 16-gauge cores averaged about 9.4 square millimeters of tissue in cross-section, versus roughly 8.0 square millimeters for 18-gauge cores. But the thicker needle also came with a catch: about 13 percent of cores taken with the 16-gauge needle contained no prostate tissue at all, compared to only 2 percent with the 18-gauge needle.¹⁰ In another randomized trial comparing the two gauges under ultrasound guidance, there was no meaningful difference in cancer detection rates, core fragmentation, or specimen quality.¹¹ So in practice, the 18-gauge needle remains the workhorse because it performs comparably while being slightly less traumatic.

Beyond gauge, needles also differ in their cutting mechanism. The standard Tru-Cut-style needle described earlier uses a notch-and-cannula design. An alternative called the end-cut needle (such as the BioPince) uses a different stroke mechanism intended to capture longer cores. Comparative testing found that the standard needle and the end-cut needle had similar low fragmentation rates only when the end-cut was set to its longest stroke length. At shorter stroke settings, the end-cut needle produced more fragmented samples and significantly more cores shorter than 5 millimeters.¹²

Pain Management During the Procedure

The biopsy firing itself is fast enough that each individual core causes only a brief sharp sensation. But the cumulative effect of 12 or more firings, plus the discomfort of the ultrasound probe, adds up. The standard pain-control technique is a periprostatic nerve block, where the urologist injects a local anesthetic near the nerve bundles at the base of the prostate before beginning the sampling. A large body of evidence from randomized trials and meta-analyses confirms that periprostatic nerve block provides substantial pain relief during the procedure, and patients undergoing repeat biopsies typically report significantly less pain when the block is used.¹³

Where exactly the block is placed also matters. A study comparing injection at the base of the prostate alone versus injections at both the base and the apex found that the two-site approach provided better overall pain control across all biopsy methods, including systematic, cognitive-fusion, and software-fusion biopsies.¹⁴ In another trial, oral tramadol provided meaningful pain reduction at all stages of the procedure except the post-procedure period, and was comparable to the injectable nerve block during the biopsy itself.¹⁵

Even body position makes a measurable difference. A randomized trial found that lying on your side (left lateral decubitus position) produced significantly lower pain scores than the lithotomy position, where your legs are elevated in stirrups, with median pain scores of about 3 out of 10 versus 5 out of 10.¹⁶ If your doctor offers a choice, lying on your side is worth considering.

Common Side Effects and Complications

Blood in the urine and blood in the semen are the most frequent aftereffects. A systematic review of biopsy complications confirmed that both are common but typically mild and resolve on their own.¹⁷ A prospective study tracking semen changes after biopsy found that 90 percent of men who were able to ejaculate experienced blood-tinged semen, with an average duration of about four weeks.¹⁸ Some degree of anxiety around this symptom is understandable, but it does not signal a serious problem.

Infection is the more worrisome complication, particularly after transrectal biopsies. One multicenter randomized trial tested whether tailoring antibiotic prophylaxis based on a rectal swab culture (to identify which bacteria are actually present) could beat the standard one-size-fits-all antibiotic approach. The culture-guided group had an infection rate of about 2.5 percent within seven days, compared to 4.3 percent with empirical antibiotics, though the difference did not quite reach statistical significance.¹⁹

Disposable Versus Reusable Needle Guides

The needle guide is the small channel attached to the ultrasound probe that holds and directs the biopsy needle. Historically, these were reusable and cleaned between patients. One study found that switching to disposable needle guides significantly lowered infectious complication rates after transrectal biopsy.²⁰ However, a separate small study comparing the two found no meaningful difference in urinary tract infection rates.²¹ The conflicting results make a clear-cut recommendation difficult, but the general trend in practice has been toward disposable guides, partly because the cost difference is small and the potential infection-control benefit is meaningful even if not guaranteed.

MRI-Compatible Needles and Their Trade-offs

Some biopsies are done entirely inside an MRI scanner, which means the needle and device must be made from non-ferromagnetic materials. Standard biopsy needles are made from stainless steel alloys that would be dangerous and produce unusable images inside a strong magnetic field. MRI-compatible systems use materials like nickel-titanium (nitinol) or ceramics. The drawback is performance: an in vitro comparison found that MRI-compatible biopsy systems produced tissue specimens roughly half the cross-sectional area of those from a conventional stainless-steel system, a statistically significant difference.²² Smaller specimens give the pathologist less tissue to evaluate. This is one reason MRI-ultrasound fusion, which uses the MRI for planning but the biopsy itself with standard equipment under ultrasound, became more popular than in-bore MRI biopsy for most clinical settings.

Robotic Biopsy Systems

Robotic platforms for prostate biopsy are still largely in the research phase, but the engineering is advancing quickly. These systems aim to combine the imaging advantages of MRI with precise mechanical needle placement. One robotic system designed for use inside an MRI scanner demonstrated a manipulator targeting accuracy of 0.71 millimeters after calibration, with a repeatability of just 0.13 millimeters. The overall system error, including the contribution of needle-tissue interaction, was about 2.4 millimeters in a soft phantom mimicking prostate tissue. Sterilization had no noticeable effect on accuracy.²³ A separate five-degree-of-freedom robotic system tested inside a 3-Tesla MRI magnet achieved an average needle placement error of 2.5 millimeters using a standard 18-gauge bevel-tip needle, and the teleoperated needle driver tracked the operator’s commands with sub-millimeter accuracy and no perceptible delay.²⁴

These error margins might sound large if you are thinking about surgery, but for biopsy purposes they are quite good. Most prostate lesions flagged on MRI are at least 5 to 10 millimeters across, so a 2.5-millimeter placement error still lands the needle well within the target zone. The bigger hurdle for robotic systems is not accuracy but cost, workflow integration, and the need to operate inside the cramped bore of an MRI machine.

What Happens After the Needle Fires

Once the tissue cores are collected, each one is placed in a labeled container with preservative solution and sent to a pathology lab. Processing matters as much as collection. Guidelines from the European Randomised Study of Screening for Prostate Cancer recommended standardized embedding techniques to ensure that the thin, fragile cores are oriented correctly when sliced for microscope slides.²⁵ A poorly embedded core might be cut at the wrong angle, missing cancer that is actually present in the sample. Each core is typically labeled by its anatomical location in the prostate so the pathologist can map where cancer was found and how extensive it is. A typical session produces 12 to 14 cores, sometimes more if additional targeted cores are taken from suspicious MRI lesions.

Liquid Biomarkers and the Future of Fewer Biopsies

For all the engineering sophistication of modern biopsy tools, the ideal scenario for many patients would be avoiding the procedure entirely when it is not needed. A significant proportion of men biopsied based on elevated PSA levels turn out not to have clinically significant cancer. Urinary and blood-based biomarker tests are increasingly used to refine the decision about who actually needs a biopsy. Tests such as PCA3, MyProstateScore, SelectMDx, and ExoDx Prostate IntelliScore can help stratify risk and steer men with borderline PSA values away from unnecessary procedures.²⁶ Biomarkers with strong negative predictive values are especially useful here: if a test can reliably tell you that you almost certainly do not have aggressive cancer, you and your doctor may reasonably decide to monitor with repeat PSA testing rather than proceeding straight to biopsy.²⁷ These tools do not replace the biopsy for diagnosis, but they are changing the conversation about when a biopsy is worth the discomfort and risk.